Page 11 Bain Capital Healthcare

Our recent investments reflect the possibilities we see and our
commitment to driving positive outcomes for patients.
Capitalized Cidara
Therapeutics to re-acquire
universal seasonal and
pandemic influenza vaccine
candidate from J&J and
fund clinical development.
Merged HealthEdge
and UST HealthProof to
create a single, end-to-
end platform that helps
payers modernize their
operations.
Immunology
Platform
Formed independent
biopharma company in
partnership with Bristol
Myers Squibb to focus on
developing novel therapies
for autoimmune diseases.
Invested scale capital in
a new company created
to advance promising
injectable and oral
metabolic-obesity drug
candidates.
Recapitalized market-
leading CDMO to focus
on injectable drugs
and advanced delivery
devices.
Led the global carve-
out of Tanabe Pharma
from Mitsubishi Chemical
to stand up a scale,
independent Japanese
pharmaceutical company.
Led recapitalization of
European market-leading
healthcare provider
software business to drive
product development and
continued international
expansion.
Merged Suvoda and
Greenphire to create
a scale, cloud-native
eClinical software platform
focused on improving
clinical trial conduct and
payments.
Investing in possibility
As we look ahead to new opportunities, we also celebrate the value realized through these four recent exits and
partial monetizations. Together, these milestones demonstrate our sustained focus on growth and impact.
For a full list of Bain Capital healthcare investments, see page 52.
11
Bain Capital Healthcare Overview